CRTX
Cortexyme, Inc.
Set alert
1.95 0.00 0.00%
1.86 Day range 1.97
52-week range unavailable
- Open
- 1.91
- Prev close
- 1.95
- Mkt cap
- 70.49M
- Vol
- 272.21K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.86
- High
- 1.97
- Forward P/E
- -1.07
- Beta
- 1.40
- Short ratio
- 6.84
- Inst. own
- 40.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2022
- 50-d avg
- 2.41
- 200-d avg
- 6.70
- 1y target
- 22.25
Key statistics
- Market cap
- 70.49M
- Enterprise value
- -32.39M
- Trailing P/E
- 0.00
- Forward P/E
- -1.07
- PEG ratio
- -0.04
- Price / sales
- 0.00
- Price / book
- 0.55
- EPS (TTM)
- -2.96
- Beta
- 1.40
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -32.47M
- Total cash
- 91.52M
- Total debt
- 339.00K
- Return on equity
- -67.33%
- Shares outstanding
- 36.15M
- Short % of float
- 14.39%
- 50-day average
- 2.41
- 200-day average
- 6.70
Analyst view
Consensus: hold
Hold
Price target (mean) 22.25 +1041.0% upside
Now 1.95
- Target (low)
- 3.00
- Target (mean)
- 22.25
- Target (high)
- 96.00
Ratings (0m) 1 0 buy · 0 hold · 1 sell
- Strong buy0
- Buy0
- Hold0
- Sell0
- Strong sell1
Next earnings
Aug 8, 2022
Expected Aug 8, 2022. Consensus EPS estimate -0.58.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 8, 2022 | Jun 1, 2022 | -0.74 | — | — | — |
| May 10, 2022 | Mar 1, 2022 | -0.64 | — | — | — |
| Mar 1, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
| Oct 29, 2021 | Sep 1, 2021 | -0.73 | — | — | — |
| Aug 9, 2021 | Jun 1, 2021 | -0.70 | — | — | — |
| May 10, 2021 | Mar 1, 2021 | -0.63 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 11, 2022 | Credit Suisse | main | — | Underperform |
| Mar 9, 2022 | HC Wainwright & Co. | main | — | Buy |
| Jan 28, 2022 | Canaccord Genuity | down | Buy | Hold |
| Jan 27, 2022 | JMP Securities | down | Market Outperform | Market Perform |
| Oct 27, 2021 | B of A Securities | down | Neutral | Underperform |
| Oct 27, 2021 | HC Wainwright & Co. | main | — | Buy |
About Cortexyme, Inc.
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cortexyme.com
News
- Financial Comparison: SQZ Biotechnologies (NYSE:SQZ) vs. Cortexyme (NASDAQ:CRTX)
- Cortexyme (NASDAQ:CRTX) and SQZ Biotechnologies (NYSE:SQZ) Critical Review
- Sorrento Therapeutics (NASDAQ:SRNE) and Cortexyme (NASDAQ:CRTX) Head to Head Analysis
- Critical Contrast: Cortexyme (NASDAQ:CRTX) vs. Eloxx Pharmaceuticals (NASDAQ:ELOX)
- Cortexyme (NASDAQ:CRTX) versus Eloxx Pharmaceuticals (NASDAQ:ELOX) Critical Contrast
- Cortexyme (NASDAQ:CRTX) & Eloxx Pharmaceuticals (NASDAQ:ELOX) Head to Head Survey
- Cortexyme (NASDAQ:CRTX) vs. Prime Medicine (NYSE:PRME) Critical Review
- Cortexyme (NASDAQ:CRTX) Stock Passes Above Two Hundred Day Moving Average – What’s Next?
- Stocks That Hit 52-Week Lows On Thursday
- Stocks That Hit 52-Week Lows On Tuesday
Your note
Sign in to keep a note on CRTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DETKE MICHAEL J | Officer | Stock Award(Grant) | Mar 2, 2022 | 140,000 |
| HANNAH BRENDAN | Officer | Stock Award(Grant) | May 18, 2022 | 16,224 |
| HOLSINGER LESLIE | Officer | Stock Award(Grant) | Mar 2, 2022 | 159,000 |
| LAMOND DAVID A. | Director | Stock Award(Grant) | May 18, 2022 | 0 |
| LOW PHILIP S | Director | Stock Award(Grant) | May 18, 2022 | 0 |
| LOWE CHRISTOPHER P | Chief Executive Officer | Stock Award(Grant) | Mar 2, 2022 | 265,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| EPIQ Capital Group, LLC | 13.53% | 4,079,461 | 7.95M | Mar 30, 2022 |
| Capital World Investors | 8.27% | 2,494,010 | 4.86M | Mar 30, 2022 |
| Blackrock Inc. | 4.66% | 1,404,037 | 2.74M | Mar 30, 2022 |
| Vanguard Group, Inc. (The) | 3.74% | 1,127,476 | 2.20M | Mar 30, 2022 |
| Morgan Stanley | 2.68% | 809,352 | 1.58M | Mar 30, 2022 |
| JP Morgan Chase & Company | 1.96% | 590,421 | 1.15M | Mar 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Growth Fund Of America Inc | 4.64% | 1,398,710 | 2.73M | Mar 30, 2022 |
| Smallcap World Fund | 3.59% | 1,083,613 | 2.11M | Mar 30, 2022 |
| Vanguard Total Stock Market Index Fund | 1.73% | 522,600 | 1.02M | Mar 30, 2022 |
| iShares Russell 2000 ETF | 1.47% | 443,600 | 865.02K | May 30, 2022 |
| Permanent Portfolio Fund-Permanent Portfolio | 0.99% | 300,000 | 585.00K | Apr 29, 2022 |
| Federated Hermes MDT Mid Cap Growth Fund | 0.80% | 241,052 | 470.05K | Apr 29, 2022 |